Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03531255 · ClinicalTrials.gov registry record · Phase 3
Pegcetacoplan Long Term Safety and Efficacy Extension Study
A Phase 3 study of PNH, sponsored by Apellis Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 160
- Enrollment target
- 20
- Study locations
NCT03531255: Active Phase 3 study of PNH, sponsored by Apellis Pharmaceuticals.
NCT03531255 is a Phase 3 study of PNH that is active but no longer recruiting, run by Apellis Pharmaceuticals. The registered enrollment target is 160 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (79% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03531255, a Phase 3 study of PNH, is active but no longer recruiting, sponsored by Apellis Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 160 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an Open-label, Non-Randomized, Multi-Center Extension Study. Eligible subjects will have previously completed a pegcetacoplan study.
Conditions Studied
Interventions
- DRUG Pegcetacoplan
Study Locations (20)
Other
- Cliniques Universitaires Saint-luc - Brussels
- AZ Delta - Roeselare
- Acibadem City Clinic Tokuda Hospital - Sofia
- National Specialized Hospital for Active Treatment of Haematologic Diseases - Sofia
- Hospital Center Chalon Sur Saone William Morey - Chalon-sur-Saône
- CHRU de Lille - Lille
Florida
- Cancer Specialists of North Florida - Jacksonville
- Lakes Research - Miami
Alberta
- University of Calgary - Calgary
- Alberta Health Services - Edmonton
California
- University of Southern California - Los Angeles
Colorado
- Denver Health Medical Center - Denver
Illinois
- Northwestern University - Chicago
Indiana
- Investigative Clinical Research of Indiana - Indianapolis
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2018-08-27 |
| Est. Completion | 2025-06 |
| Phase | Phase 3 |
What the registry record for NCT03531255 still lists
NCT03531255 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (79% lower).
The record links to 1 condition, with PNH appearing as the primary indexed condition, and to 1 intervention - of which Pegcetacoplan is the first listed.
NCT03531255 names 20 study sites across 13 states, led by Other, Florida, Alberta.
Frequently Asked Questions
What is clinical trial NCT03531255 about?
NCT03531255 is a clinical study titled "Pegcetacoplan Long Term Safety and Efficacy Extension Study". This is an Open-label, Non-Randomized, Multi-Center Extension Study. Eligible subjects will have previously completed a pegcetacoplan study.
What is the current status of trial NCT03531255?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 160 participants. The study started on 2018-08-27. Estimated completion is 2025-06.
What conditions does trial NCT03531255 study?
This clinical trial studies the following conditions: PNH.
What interventions are being tested in trial NCT03531255?
The interventions under investigation include: Pegcetacoplan (DRUG).
Who is sponsoring clinical trial NCT03531255?
This trial is sponsored by Apellis Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03531255 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for PNH
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03531255's enrollment target sits among peer trials
160 1480th of 2000 higher than 500 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI